Presentation on theme: "C1 inhibitor Deficiency: Why does it happen and what does it look like? Gina Lacuesta, MD FRCPC Allergy and Clinical Immunology Assistant Professor, Dalhousie."— Presentation transcript:
C1 inhibitor Deficiency: Why does it happen and what does it look like? Gina Lacuesta, MD FRCPC Allergy and Clinical Immunology Assistant Professor, Dalhousie University Nov 29,2014
Disclosure and Thank You CSL Behring -Berinert® Shire-Firazyr ® and Cinryze® -attended advisory boards, international meetings and worked with sales and medical representatives Board Member of CHAEN
objective Review the definition and causes of angioedema – why are your doctors confused about this condition? Review the pathophysiology of C1 inhibitor deficiency – today you are a medical student! Review the clinical presentation of C1 inhibitor deficiency – does this sound like you?
Angioedema ANGIO – vessel EDEMA – swelling Soft tissue swelling usually located around the eyes, lips, face, ears, tongue, hands, feet Usually asymmetrical In C1 inhibitor deficiency, intestinal angioedema is common with abdominal pain and urinary difficulties Laryngeal edema can be life threatening
As opposed to….EDEMA Swelling in dependant areas, ie feet, ankles, even sacral swelling, scrotal swelling, at end of day and around the eyes first thing in the morning Related to fluid shifts/fluid retention/salt and water balance Strongly associated with heart disease, liver disease, malnutrition, severe illness, ‘hormonal’ fluctuations
Picture of pitting edema
Non HAE Angioedema – causes Allergy Cause is easily identifiable Food, drug, sting Can be life threatening Often associated with hives Often easy to figure out the allergic culprit With avoidance, most patients can live ‘normal’ lives Responds to epinephrine, antihistamines and steroids
Non HAE Angioedema - causes DRUGS Aspirin/NSAIDs/anti-inflammatories ACE- inhibitors Well described phenomena; often forgotten about Quinke’s edema Uvula swelling only, repeatedly Often as a rebound reaction to dryness in the throat Occasionally, surgery used to correct
Non HAE Angioedema - causes Infection Mostly, viral related Common, 1:10 will experience hives or angioedema, unexplained at least once in their lifetime Usually short lived, ie lasting a few months maximum, most often benign
Non HAE Angioedema - causes Chronic spontaneous/autoimmune Often associated with hives Can happen daily for months/years Diagnosis of exclusion, ie. No other cause found Benign, most easily managed with well tolerated medications, ie antihistamines Newer treatments: Xolair ®, rarely immunosuppressants Common condition
Angioedema- why are your doctors confused Compared to the previous, C1 inhibitor deficiency is very rare, and rarely, if at all taught in medical school Doctors ARE aware of the other causes, and are AFRAID of the other causes EVERYONE wants the angioedema to be managed by steroids/antihistamines/epinephrine and AVOIDANCE of food!…but it doesn’t work that way
Why is diagnosing C1 inhibitor deficiency an issue? Documented failure to recognize and diagnose HAE-22 year delay in survey by Frank et. al. (Ann Int Med. 1976;84:580) Delay still observed in recent survey Age at diagnosis: 16.8 yrs (range 1-42 yrs) Age when sx began: 7.8 yrs (range 1-18 yrs) Delay in diagnosis: 9.1 yrs (range 0-32 yrs) Failure to diagnose dramatically increases the risk of significant M&M
HAE/C1 inhibitor deficiency
What is complement? Part of our INNATE immune system Present in everyone as a PRIMITIVE defense mechanism against infection As opposed to our ACQUIRED immune system which adapts based on our exposures, either via infection or vaccination COMPLEMENT helps our ACQUIRED immune system do its job, therefore, the term COMPLEMENT
Picture of complement cascade
Importance of C1 inhibitor Controls bradykinin formation Bradykinin causes blood vessels to dilate and become permeable, ie leak fluid into the soft tissues, thus, swelling If bradykinin is allowed to produce repeatedly, if it does not get broken down and destroyed, and if its receptor is not blocked….there will be increased chances of swelling, inflammation and pain
C1 inhibitor deficiency
HAE nomenclature HAE Type 1 – HAE due to C1 deficiency with low levels and functional assay HAE Type 2 – HAE due to C1 dysfunction with normal levels and low functional assay HAE Type 3 – HAE with normal C1 levels and functional assay
HAE type 1 and 2 1:50,000 Autosomal dominant; mutations of the SERPING1 gene 25% de novo mutation rate Bradykinin is the main mediator of swelling Bradykinin produced when kallikrein cleaves HMW kininogen. Kallikrein activated by factor XII Kallikrein and factor XII both normally inhibited by C1 inhibitor.
Features of HAE-Normal C1INH Compared to HAE-C1INH Deficiency – Bork 2007 Normal C1INH protein level and activity Predominantly women clinically affected Symptom onset in adulthood more common, rarely affects children Less frequent symptoms with longer symptom-free Intervals Facial and lip swelling more frequent Recurrent tongue swelling a cardinal symptom Many patients have only skin swelling Abdominal attacks less frequent Asphyxiation due to airway involvement occurs No erythema marginatum; hemorrhages into skin swelling has been observed
How patients present Angioedema without urticaria, can have non-pruritic serpiginous rash Angioedema mostly face, limbs, gut Can have profound pain syndromes, vomiting, diarrhea, voiding difficulties Attacks prolonged but do not occur daily; latency period “Average” untreated patient will swell q10-14 days, lasting 48-72h Enormous range of severity between patients Substantial morbidity seen in patient surveys Risk of death from laryngeal angioedema, mortality rate of 30% if left untreated
Angioedema most commonly involves the abdomen ⁴, face, extremities, genitals, and larynx.¹ Skin attacks are the most common and usually manifest as disfiguring, nonpitting, and sometimes painful skin swelling affecting most commonly the extremities, face, and genitals.² Abdominal attacks occur in 70%-80% of patients with recurrent abdominal pain caused by edema in the stomach or intestinal wall and free fluid in the peritoneal cavity.³ Laryngeal attacks occur at least once in a patient’s lifetime in 50% of the cases. These attacks are usually classified as severe—as airway obstruction could be fatal—with mortality rates as high as 30% if left untreated or undiagnosed. 2, 4 Angioedema most commonly involves the abdomen ⁴, face, extremities, genitals, and larynx.¹ Skin attacks are the most common and usually manifest as disfiguring, nonpitting, and sometimes painful skin swelling affecting most commonly the extremities, face, and genitals.² Abdominal attacks occur in 70%-80% of patients with recurrent abdominal pain caused by edema in the stomach or intestinal wall and free fluid in the peritoneal cavity.³ Laryngeal attacks occur at least once in a patient’s lifetime in 50% of the cases. These attacks are usually classified as severe—as airway obstruction could be fatal—with mortality rates as high as 30% if left untreated or undiagnosed. 2, 4 1. Khan D A, Allergy Asthma Proc 2011; 32:1-10; 2. Banerji A,Allergy Asthma Proc 2011; 32: ; 3. Caballero T, J Investig Allergol Clin Immunol 2011;21(5): 333 ; 4. Bork K. et al. Am J Med 2006; 119: The probability that a given attack will involve the skin or abdomen is nearly 50% each. All other attack locations, including genitourinary and laryngeal attacks, account for only 3.6% of attacks. ⁴ Most attacks affect the skin or abdomen
Frequency of HAE Attacks Attack frequency, severity, and course vary among patients, and even for a single patient depending on stage of life 1,2,3 Less than one attack per year to more than 26 attacks per year Mean of 27 attacks /year Median 12 attacks/ year per patient In some rare cases, patients can experience more than 100 attacks per year No evident correlation between: Attack frequency and plasma levels of C1-INH Number of attacks from one year and the next Frequency of attacks in family members Although precipitated by known factors, attacks may occur without obvious trigger 1,3 1 Gompels MM, et al. Clin Exper Immunol. 2005;139(3): Kaplan AP. J Allergy Clin Immunol. 2010;126(5): Frank MM Ann Intern Med. 1976;84:580ñ593
C1 inhibitor deficiency- acquired form AAE-symptoms the same no family history later onset, usually after age 60 often associated with hematological malignancies, ie lymphoma, monoclonal gammopathy, or autoimmune diseases Often with low C1q levels Mechanism felt to be autoimmune, increased metabolism of C1 inhibitor, unknown Mainstay is to treat the underlying condition, but also to be aware of usual C1 inhibitor treatment, can become resistant to treatment, requiring increasing doses of C1 inh replacement Rarer than HAE
Health-Related QOL Decreases in Patients With HAE QOL=quality of life; SF-12=Short Form Health Survey. Adapted from Lumry WR, et al. Allergy Asthma Proc. 2010;31(5): Patients with HAE are also significantly more likely to experience symptoms of depression compared with population norms (P<.0001) Up to 70% of patients report that HAE has affected their educational and career goals and that they may be unable to realize their potential due to high levels of anxiety and depression Patients with HAE experience a decline in productivity comparable with patients with severe asthma or Crohn’s disease 43.7 ± ± ± ± Physical Component Summary Mental Component Summary Mean SF-12 Score Normative Population Patients With HAE N=457 P<.0001 Shire Proprietary & Confidential Information
Days Missed During Most Recent HAE Attack b Patients Affected a a Number of patients affected during most recent attack of HAE. b Mean number of days missed during most recent attack of HAE. Lumry WR, et al. Allergy Asthma Proc. 2010;31(5): Work Days (n=156) School Days (n=12) Leisure Days (n=271) Work Days (n=308) School Days (n=27) Leisure Days (n=457) 3.3 ± ± ± Patients Missing Days (%) Mean Number of Days Missed HAE Attacks Adversely Impact Work, School, and Leisure Activities Shire Proprietary & Confidential Information
Management of C1 inhibitor deficiency Gina Lacuesta, MD FRCPC Allergy and Clinical Immunology Assistant Professor, Faculty of Medicine Dalhousie University Nov 29, 2014
Objectives What are the goals of care? What did treatment look like BEFORE and what was the problem? What does treatment look like now? What can we do better?
Previous goals of care Make the right diagnosis! Recognize that the condition is hereditary and screen the family Keep the patients ALIVE Keep the patients out of the ER
New goals of care Improving quality of life Treatment should aim to maximize patient health by Aborting acute attacks to prevent morbidity and mortality Minimize significant side effects Avoid disruption of normal life, ie school, work, family life
Past treatment: side effects
In with the NEW….US data
In Canada: June 2010 : Berinert® fully approved for use in HAE 2012: Cinryze® approved in Canada, still waiting for its full release 2014: Firazry® approved in Canada
In Maritimes: 2011 First patient on prophylactic Berinert, early Spring patients being arranged In Hospital treatment only…thus far
In Maritimes: 2013 NS: 5 patients on prophylaxis( 4 self infusion/1 in hospital ) NB: 1 patient on prophylaxis( line in place, home) PEI: 1 patient on prophylaxis (line in place, in hosp) NS: 1 patient on demand(self), 1 due to be taught NB: 1 patient on demand (self)
In Maritimes: 2013 Still some patients on oral medications for on demand and prophylaxis and this works well for them 5 acquired C1 inhibitor deficiency patients, 1 of which is on prophylaxis.
In Maritimes: 2014 NS: 8 patients on Prophylaxis with Berinert NB: 1 patient on Prophylaxis with Berinert PEI: 1 patient on prophylaxis with Berinert 10 others On Demand Berinert treatment, or prophylaxis with medications 6 with Firazyr On Demand, a few others in the works for approval
C 1 inhibitor
C1 inhibitor –eliminates the underlying cause by replacing the deficient protein Berinert®-CSL Behring 20U/kg, slow IV push 50kg 1500U Indicated for acute attacks Half life 32-47h Well tolerated Off label use with high doses in neonates resulted in thrombotic events Cinryze®- Shire 1000U, slow IV push, not based on weight Indicated for long term, routine prevention Half life 48+/- 10h Well tolerated
IMPACT2- International Multicenter Prospective Angioedema C1 inhib Craig, T. et al, Allergy, patients, 975 HAE attacks Open label extension of placebo controlled IMPACT1 trial Median time to onset of symptom relief of 15min for laryngeal attacks, 20 min for abdominal attacks, 28 min for facial attacks and 31 minutes for peripheral attacks
Nanofiltered C1 inhibitor in HAE- Zuraw, et al, Am J Med, 2012 Open label multi center extension study, 146 patients with HAE treated for 2.6y with prophylaxis Cinryze® 1000U every 3-7 days 93.7% reduction in attacks compared with historical rate of attacks 87.7% had 1 attack or less per month 34.9% had no attacks Twice weekly seemed to have the best control, though sub group responded to once a week, no predictors found
C1 inhibitor self infusion- Maritimes Currently, all teaching has been done by hemophilia nursing, with follow up and support as needed Berinert® does come with option to be taught by private nursing ??Cinryze® to have a comprehensive training program established, based on education and training practices already used in the US, My Path TM, with ongoing support
Characteristics of Icatibant Synthetic decapeptide with structure similar to bradykinin Indicated for the treatment of acute attacks of HAE in adults with C1-esterase inhibitor deficiency Delivered by subcutaneous (SC) injection in the abdomen Provided in a single-use, pre-filled syringe containing 30 mg (10 mg/mL) that can be stored at room temperature Shire Proprietary & Confidential Information H 2 N H N O O HN H 2 NNH HN H 2 NNH N ON N H H N O N H O N O NO H N OH O NH NHH 2 N HO OH O S H H O HO O CH 3 n Shire Human Genetic Therapies (Canada) Inc. Firazyr Product Monograph. June 4, 2014.
Endpoints Measure Onset and Resolution of Symptoms Almost complete symptom relief (All VAS < 10mm) Beginning of attack Initial symptom improvement Time t=0 Time course of a treated attack Symptom severity of a treated attack Treatment administration Onset of symptom relief (VAS ) earliest of 3 consecutive measures Shire Proprietary & Confidential Information
FAST 2: Time to Onset of Primary Symptom Relief Primary endpoint Median95% CIp-value Icatibant <0.001 Tranexamic Acid Tranexamic Acid Icatibant 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% % of Patients Not Achieving Symptom Relief Hours After Treatment Primary symptom relief is defined as a reduction of at least 30% from pre-treatment in the score for primary VAS; has to sustain for 3 consecutive non-missing measurements Cicardi M, et al. N Engl J Med. 2010;363: Erratum in: N Engl J Med. 2010;363:1468. ITT non-laryngeal population VAS Shire Proprietary & Confidential Information
FAST-3: Study Design and Patient Disposition Lumry W et al. Ann Allergy Asthma Immunol. 2011; 107: Abdominal and/or cutaneous attack (n=88) Laryngeal attack (n=10) Treatment of subsequent attacks (cutaneous, abdominal, or laryngeal) Double-blind treatment: Icatibant vs placebo (n=43) (n=45) Open-label extension phase Icatibant 30 mg SC up to 3 x per attack; no more than 8 injections per month (n=82 pts) First eligible attack (n=98) Mild to moderate attack Severe attack Double-blind treatment: Icatibant vs placebo (n=3) (n=2) Open-label treatment: icatibant (n=5) Moderate to severe attack Shire Proprietary & Confidential Information
% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% % of Patients Not Achieving Symptom Relief Median95% CIp-value Icatibant2.01.5, 3.0<0.001 Placebo , 26.3 Placebo (n=45) Icatibant (n=43) Hours After Treatment FAST-3: Time to Onset of Symptom Relief Primary endpoint ITT population VAS 3 (abdominal pain, skin pain, and skin swelling) Lumry W et al. Ann Allergy Asthma Immunol. 2011; 107: Shire Human Genetic Therapies (Canada) Inc. Firazyr Product Monograph. June 4, Shire Proprietary & Confidential Information Onset of symptom relief is defined as a 50% reduction from pre-treatment in VAS 3 score; has to sustain for 3 consecutive non-missing measures
FAST-3: Time to Almost Complete Symptom Relief Secondary endpoint Median95% CIp-value Icatibant8.05.0, Placebo , 50.9 Placebo Icatibant 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% % of Patients Not Achieving Symptom Relief Hours After Treatment Lumry W et al. Ann Allergy Asthma Immunol. 2011; 107: Shire Human Genetic Therapies (Canada) Inc. Firazyr Product Monograph. June 4, ITT population VAS 3 (abdominal pain, skin pain, and skin swelling) Shire Proprietary & Confidential Information Almost complete symptom relief is defined as all VAS scores ≤ 10 mm; has to sustain for 3 consecutive non-missing measurements
FAST-3: Icatibant Laryngeal Attack Efficacy Comparable to Abdominal or Cutaneous Laryngeal Treated Events including open label extension trial Icatibant (N=27attacks) Median time to onset of symptom relief as measured by VAS-5; hours (95% CI) 2.2 (1.5, 3.5) Median time to onset of primary symptom relief; hours (95% CI) 2.2 (1.5, 3.5) Median time to almost complete symptom relief; hours (95% CI) 6.2 (3.0, 24.3) Shire Proprietary & Confidential Information
Laryngeal Attacks: Time to Initial Symptom Improvement % of Patients Not Achieving Symptom Relief First laryngeal attack Shire Proprietary & Confidential Information ISE Table 11.5
FAST OLE: Analysis of HAE Attacks Requiring Reinjection of Icatibant Bernstein JA, et al. Poster presented at: American College of Allergy, Asthma and Immunology (ACAAI) 2013 Annual Scientific Meeting; November 7-11, 2013; Baltimore, MD. Poster P90. Berstein et al. Poster presented at AAAAI 2014 Analysis of pooled data from all FAST OLE studies. Total # pts in FAST OLE: 225. Total # of attacks treated: 1149 Total # pts with laryngeal attacks in FAST OLE: 52. Total # of attacks treated: injection 2 injections 3 injections 1 injection + other acute HAE treatment 0.5% 0.9% 90.4%8% 91.8% 7.3% 1.1% More than 90% of HAE attacks were treated with a single icatibant injection regardless of location. Icatibant reinjection was infrequent and appeared to be independent of patient age, patient sex, HAE type, and initial attack severity. All attacks Laryngeal Attacks
Safety Profile Shire Human Genetic Therapies (Canada) Inc. Firazyr (icatibant) Product Monograph. June 4, 2014.
Safety Profile The overall incidence of serious adverse events (SAEs) was low in the clinical development program In the Phase I and II studies, only 2 SAEs were reported within 14 days of FIRAZYR treatment (manic episode, HAE); these were judged as not related/probably not related to treatment. In the controlled part of the three Phase III studies, only one SAE (cystitis) was reported within 14 days of dosing with FIRAZYR. This event was judged as not related to treatment. In the repeated treatment part of the Phase III studies, safety was evaluated for up to 15 FIRAZYR-treated attacks for patients. Sixteen patients experienced a total of 22 SAEs that occurred within 14 days of FIRAZYR administration. The only SAE that occurred in more than one patient was worsening or recurrence of HAE. Two SAEs were considered by the investigator as related to FIRAZYR treatment (events of arrhythmia and noncardiac chest pain). Shire Human Genetic Therapies (Canada) Inc. Firazyr (icatibant) Product Monograph. June 4, 2014.
Injection Site Reactions are Common but Transient and Self-resolving Photos courtesy of Dr M Bas, Klinikum Rechts der Isar der TechnischenUniversität München, Munich, Germany Represents moderate severity reaction Shire Proprietary & Confidential Information 63
Icatibant Safety Profile in Open-Label Use AEs in open-label extension of phase III controlled trials (N=225) were similar in frequency and nature to those observed in the controlled / blinded phase of the trials – Rash, nausea, headache, worsening or recurrence of HAE Self-administered icatibant (N=98) displayed a safety profile similar to that of HCP-administered icatibant No hypersensitivity or anaphylactic reactions were reported in clinical trials No association between anti-icatibant antibodies and efficacy was observed Shire Human Genetic Therapies (Canada) Inc. Firazyr Product Monograph. June 4, CONFIDENTIAL 64
Ecallantide-Kalbitor® not available in Canada
Kallikrein inhibitor Inhibits cleavage of HMW kininogen to bradykinin and therefore prevents progression of angioedema attack Ecallantide- Kalbitor®- Dyax. 30mg sc injection, half life 1-2hours Has had reported anaphylaxis
Attenuated Androgens Danazol, stanazolol, oxandrolone Contraindicated in pregnancy, lactation, cancer, hepatitis, childhood Significant side effects of virilization, weight gain, acne, hair growth, altered libido, voice deepening, decreased breast size, menstrual irregularities, HTN, atherosclerosis, increased liver enzymes, cholestasis, HCC Dose varies from 100mg EOD, to 200mg TID, adjusting to clinical response More effective than antifibrinolytic agents
Antifibrinolytic agents Used in more in pediatric population, as a safer alternative to androgens, but evidence of efficacy lacking Side effects mostly GI, theoretical risk of increased thrombosis Dosing 30-50mg/kg in divided doses 2-3 times /day to max of 6g
WAO Guideline Consensus meeting in Turkey 2011 Published in WAO Journal DEC 2012
Short term/preprocedural prophylaxis Evidence is lacking, but generally considered to be a strong recommendation Dental/intraoral surgery, any procedure requiring intubation, with upper airway or pharynx manipulation, bronchoscopy or endoscopy History of frequent swellings, swelling after a similar procedure in the past Stressful periods, concurrent infections C1 inhibitor U/kg 1-6 hours before procedure, with on demand treatment available also Other options: Androgens or tranexamic acid
Long term prophylaxis Use of regular medication to prevent episodes of angioedema Takes into consideration severity of disease, frequency of attacks, patients' quality of life, availability of resources, failure to achieve adequate control with on demand therapy If more than 1 severe attack occurs per month, or treatment for severe attack is not sufficiently effective Choice between C1 inhibitor replacement, androgens, antifibrinolytic agents
Management Counseling about their disease, genetics Refer to patient support HAE groups Carry letters identifying them as a C1 inhibitor deficiency patient, urgency and how to treat Baseline viral studies and liver function studies; Hepatitis A and B vaccine, influenza vaccine
Management Depending on long term drug treatment- labs and radiology to monitor side effects Education regarding MEDS to avoid ( ACE inhibitors for blood pressure, estrogen supplements/birth control), potentially exacerbating situations(fatigue, stress, dental work, surgery, infection, etoh, menses etc)
Management C1 inhibitor to be stocked at home hospital Patients educated to be vigilant about keeping relations with blood bank, especially in remote areas
Long term care for HAE patients procedures Develop action plan Provide with HAE emergency card Provide with 2 doses of on demand therapy Screen family Hep B, C HIV screening Assessment by HAE specialist Influenza vaccine If androgens used: LFT,CBC,Lipids, UA Cardiac RF U/S liver timing At diagnosis and annually At diagnosis At diagnosis, annually if using blood product Annually Start and q 6 months Start and q 12 months Craig, et al, WAO Journal, Dec 2012
Pediatric population Attacks usually occur during school age years, in 50% of cases between age 5-11 Upper airway is rarely the initial presentation Erythema marginatum is more frequent and often mistaken for urticaria Pre-natal testing is not recommended Testing at birth is not recommended, due to false negative testing
Pediatric population If symptomatic, still need a treatment plan and on demand therapy Ecallantide and icatibant are not licensed for use in children C1 inhibitor best choice for on demand therapy Antifibrinolytics(20-40mg/kg) chosen over androgens because of side effect profile. Common triggers include infection and mechanical trauma Vaccination recommended to reduce infection Avoid use of oral estrogen contraception Educate all caregivers
Pregnancy Can either mitigate, worsen or not change the frequency of attacks at all C1 inhibitor replacement is the recommended first line therapy. Short term prophylaxis is recommended during any procedures including amniocentesis, chorionic villus sampling, surgical abortion. Not necessary with uncomplicated natural delivery, but should be available for 72hours port partum
Pregnancy C1 inhib should be given prophylactically if: HAE is known to be severe Frequent swellings in 3 rd trimester History of vaginal edema with mechanical trauma If intubation necessary With forceps or vacuum extraction needed C- section Androgens not recommended in pregnancy due to effects on the fetus, also not recommended during breastfeeding Tranexamic acid can be used if C1 inhibitor not available
AAE management Essentially the same principles, except treatment for underlying condition plays an important role May have some benefit from antihistamines, steroids as can also have an autoimmune histamine mediated angioedema along with AAE Can use either Icatibant or C1 inhibitor - On Demand, though not formally studied If prophylaxis required, can become “resistant” to C1 inhibitor replacement of may need higher than usual dosing
After these presentations, you should be able to: Define and classify HAE Know what tests are ordered to diagnose HAE/AAE. Know what other conditions your drs are thinking about and how to differentiate from them Discuss management strategies, ie on-demand, short term and long term prophylaxis How the appropriate medications and replacement are prescribed What information is important to patients and primary physicians about follow up, meds to avoid, when to be vigilant Discuss special circumstances, ie pediatric population, pregnancy Acquired angioedema Recognize and refer to international and national guidelines Be an EXPERT in HAE
What else can we do? 2011: Train and recruit more immunologists Educate local physicians/ER/nurses Maintain good working relationships with blood banks Set up self treatment program If not a candidate for self treatment program, have a plan for treatment of acute swelling attacks….stay on top of C1 stock in local hospitals 2013: Consider participating in upcoming trials Now there is CHOICE in effective, safe treatments…how do we make those choices? Be responsible with the products that we use
What else can we do? EDUCATE, EDUCATE, EDUCATE Lobby for coverage and access for all patients Comprehensive care clinics Look forward to more sc products, ? Oral products
questions How soon into an HAE attack do I take the first Firazyr injection? If I take the first injection early enough, should it stop the attack from worsening? In order to judge if Firazyr is going to be an effective treatment in decreasing an attack, would I have to use it during a couple of HAE attacks to assess the results? I used it once and I was still not well for 2-3 days afterwards.
questions If the Firazyr did not decrease my swelling after the first dose, how long should I wait before I go to the hospital? Can I take Berinert between the first dose of Firazry and the second dose of Firazyr when the first dose did not stop or decrease my swelling? If I have to try the second dose of Firazyr before taking berinert, how long do I have to wait after I take the second Firazyr to take Berinert?
questions Does Firazyr have the same drug components/ingredients in it as Berinert? I keep Firazyr in the fridge at a temperature above 2 degrees. What temperature should it be at when I administer it? For example, should I let it sit out of the fridge for a little while before I use it?
questions What is the experience of patients who have taken Firazyr ? for example how long did it for them to feel the swelling decreasing? How long did it take for the swelling to be gone completely? Have they had any side effects from it? If so what were they? For patients who took long term Danazol and is now off it, are there any tests as follow up that they should have done ?
Canadian websites HAE Canada's Physician Website: